Triptolide alleviates allergic airway inflammation by inhibiting group 2 innate lymphoid cell function

Area of Science:

• Immunology
• Pharmacology
• Traditional Chinese Medicine

Background:

• Group 2 innate lymphoid cells (ILC2s) are key players in type 2 immune responses, including allergic airway inflammation.
• Interleukin-33 (IL-33) is a critical cytokine for activating ILC2s.
• Targeting lung ILC2s with specific drugs, particularly from traditional Chinese medicine, remains underexplored.

Purpose of the Study:

• To investigate the potential of triptolide, a traditional Chinese medicine, in ameliorating allergic airway inflammation.
• To elucidate the mechanism by which triptolide affects ILC2 activation and function.
• To explore the therapeutic potential of triptolide for allergic airway diseases.

Main Methods:

• Utilized an experimental model of allergic airway inflammation.
• Administered triptolide to assess its effects on ILC2s and inflammation.
• Performed RNA sequencing (RNA-seq) to analyze gene expression changes in ILC2s.
• Challenged triptolide-treated ILC2s with IL-33 to assess functional impairment.

Main Results:

• Triptolide significantly ameliorated allergic airway inflammation.
• Triptolide suppressed the activation and function of ILC2s in response to IL-33.
• RNA-seq analysis revealed triptolide's impact on inflammation-related signaling pathways and ILC2-related gene expression (e.g., IL-5, IL-13).
• Triptolide demonstrated both preventive and therapeutic effects.

Conclusions:

• Triptolide effectively suppresses ILC2 activation, thereby ameliorating allergic airway inflammation.
• Triptolide modulates key inflammation-related signaling pathways and gene expression in ILC2s.
• Triptolide shows promise as a therapeutic agent for allergic airway inflammation, targeting ILC2s.